BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/12/2026 10:07:37 AM | Browse: 16 | Download: 63
 |
Received |
|
2025-08-18 08:27 |
|
Peer-Review Started |
|
2025-08-18 08:27 |
|
First Decision by Editorial Office Director |
|
2025-09-04 07:14 |
|
Return for Revision |
|
2025-09-04 07:14 |
|
Revised |
|
2025-09-14 14:32 |
|
Publication Fee Transferred |
|
2025-09-23 09:38 |
|
Second Decision by Editor |
|
2025-11-19 02:37 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-19 08:27 |
|
Articles in Press |
|
2025-11-19 08:27 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-01-04 01:11 |
|
Publish the Manuscript Online |
|
2026-01-12 10:07 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Toshihiko Matsumoto, Soma Sugimoto, Reo Omori, Chinatsu Makiyama, Akio Nakasya, Hiroki Nagai, Hisateru Yasui, Reiji Higashi, Akitoshi Sasamoto and Hironaga Satake |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Toshihiko Matsumoto, Associate Chief Physician, MD, PhD, Department of Medical Oncology, Ichinomiyanishi Hospital, 1 Kaimei Aza Hira, Ichinomiya 4940001, Aichi, Japan. makoharutaro2015@gmail.com |
| Key Words |
Gastric cancer; Ascites; Nivolumab; Chemotherapy plus nivolumab; Immune checkpoint inhibitor |
| Core Tip |
The combination of chemotherapy and immune checkpoint inhibitors has become standard therapy for advanced gastric cancer (AGC). However, data on efficacy in patients with AGC and high ascites burden (HAB) remain limited. Chemotherapy combined with nivolumab has demonstrated modest efficacy in AGC patients with HAB (progression-free survival: 4.4 months; overall survival: 7.3 months). Chemotherapy with nivolumab improved ascites in 56% of patients. Furthermore, these results showed no correlation with programmed cell death ligand 1 (PD-L1) expression. These results suggest that nivolumab chemotherapy could be a therapeutic option for patients with AGC and HAB, regardless of PD-L1 expression. |
| Publish Date |
2026-01-12 10:07 |
| Citation |
Matsumoto T, Sugimoto S, Omori R, Makiyama C, Nakasya A, Nagai H, Yasui H, Higashi R, Sasamoto A, Satake H. Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites. World J Gastrointest Oncol 2026; 18(1): 112944 |
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i1/112944.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v18.i1.112944 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
